Browse result page of SalivaDB
This is the result page of the browse module of SalivaDB. This page gives the information about the query submitted by the user as per the browse category. Further details of the entries can be seen by clicking on the SAL_ID. Further the user can sort the entries on the basis of various fields by clicking on the respective headers. The user can also download the results in various formats.
Tabular representation:
SAL_ID | Biomarker Name | Biomarker Type | Analysis Method | Collection Site | Disease/Condition Category | Disease/Condition | Disease/Condition Subtype | Fold Change | Regulation | Exosomal Origin | Organism | PMID | YOP | External Links | Biomarker Category | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
SAL_10315 | Beta actin | NA | iTRAQ + ELISA | Unstimulated Saliva | Premalignant Disorder | Oral potentially malignant disorders | NA | 0.82 | Downregulated | NA | Homo sapiens | 30169911 | 2018 | K4ENJ5 | ProteinSAL_10317 | cDNA, FLJ92374, highly similar to Homo sapiens | NA | iTRAQ + ELISA | Unstimulated Saliva | Premalignant Disorder | Oral potentially malignant disorders | NA | 1.26 | Upregulated | NA | Homo sapiens | 30169911 | 2018 | B2R582 | Protein | SAL_10319 | Cystatin-A | NA | iTRAQ + ELISA | Unstimulated Saliva | Premalignant Disorder | Oral potentially malignant disorders | NA | 0.72 | Downregulated | NA | Homo sapiens | 30169911 | 2018 | P01040 | Protein | SAL_10321 | Fibrinogen gamma chain | NA | iTRAQ + ELISA | Unstimulated Saliva | Premalignant Disorder | Oral potentially malignant disorders | NA | 1.44 | Upregulated | NA | Homo sapiens | 30169911 | 2018 | P02679 | Protein | SAL_10323 | HCG40889, isoform CRA_b | NA | iTRAQ + ELISA | Unstimulated Saliva | Premalignant Disorder | Oral potentially malignant disorders | NA | 1.25 | Upregulated | NA | Homo sapiens | 30169911 | 2018 | A0A024R962 | Protein | SAL_10325 | Hemopexin | NA | iTRAQ + ELISA | Unstimulated Saliva | Premalignant Disorder | Oral potentially malignant disorders | NA | 1.33 | Upregulated | NA | Homo sapiens | 30169911 | 2018 | P02790 | Protein | SAL_10327 | Immunoglobulin lambda variable 4-60 | NA | iTRAQ + ELISA | Unstimulated Saliva | Premalignant Disorder | Oral potentially malignant disorders | NA | 0.77 | Downregulated | NA | Homo sapiens | 30169911 | 2018 | A0A075B6I1 | Protein | SAL_10329 | Inositol monophosphatase 2 | NA | iTRAQ + ELISA | Unstimulated Saliva | Premalignant Disorder | Oral potentially malignant disorders | NA | 0.78 | Downregulated | NA | Homo sapiens | 30169911 | 2018 | O14732 | Protein | SAL_10331 | Inter-alpha-trypsin inhibitor heavy chain H4 | NA | iTRAQ + ELISA | Unstimulated Saliva | Premalignant Disorder | Oral potentially malignant disorders | NA | 1.24 | Upregulated | NA | Homo sapiens | 30169911 | 2018 | B7ZKJ8 | Protein | SAL_10333 | Interleukin-1 receptor antagonist protein | NA | iTRAQ + ELISA | Unstimulated Saliva | Premalignant Disorder | Oral potentially malignant disorders | NA | 0.75 | Downregulated | NA | Homo sapiens | 30169911 | 2018 | P18510 | Protein | SAL_10335 | MS-F1 heavy chain variable region | NA | iTRAQ + ELISA | Unstimulated Saliva | Premalignant Disorder | Oral potentially malignant disorders | NA | 0.76 | Downregulated | NA | Homo sapiens | 30169911 | 2018 | A0A125U0V1 | Protein | SAL_10337 | Neutrophil defensin 1 | NA | iTRAQ + ELISA | Unstimulated Saliva | Premalignant Disorder | Oral potentially malignant disorders | NA | 0.55 | Downregulated | NA | Homo sapiens | 30169911 | 2018 | P59665 | Protein | SAL_10339 | Plasma protease C1 inhibitor | NA | iTRAQ + ELISA | Unstimulated Saliva | Premalignant Disorder | Oral potentially malignant disorders | NA | 1.23 | Upregulated | NA | Homo sapiens | 30169911 | 2018 | E9PGN7 | Protein | SAL_10341 | Protein AMBP | NA | iTRAQ + ELISA | Unstimulated Saliva | Premalignant Disorder | Oral potentially malignant disorders | NA | 1.32 | Upregulated | NA | Homo sapiens | 30169911 | 2018 | P02760 | Protein | SAL_10343 | Prothrombin | NA | iTRAQ + ELISA | Unstimulated Saliva | Premalignant Disorder | Oral potentially malignant disorders | NA | 1.34 | Upregulated | NA | Homo sapiens | 30169911 | 2018 | P00734 | Protein | SAL_10345 | S100 calcium-binding protein A2 | NA | iTRAQ + ELISA | Unstimulated Saliva | Premalignant Disorder | Oral potentially malignant disorders | NA | 1.73 | Upregulated | NA | Homo sapiens | 30169911 | 2018 | P29034 | Protein | SAL_10347 | Serpin family B member 10 | NA | iTRAQ + ELISA | Unstimulated Saliva | Premalignant Disorder | Oral potentially malignant disorders | NA | 0.76 | Downregulated | NA | Homo sapiens | 30169911 | 2018 | Q4VAX6 | Protein | SAL_10349 | Solute carrier family 3 member 2 | NA | iTRAQ + ELISA | Unstimulated Saliva | Premalignant Disorder | Oral potentially malignant disorders | NA | 1.38 | Upregulated | NA | Homo sapiens | 30169911 | 2018 | J3KPF3 | Protein | SAL_10351 | Thioredoxin | NA | iTRAQ + ELISA | Unstimulated Saliva | Premalignant Disorder | Oral potentially malignant disorders | NA | 0.77 | Downregulated | NA | Homo sapiens | 30169911 | 2018 | H9ZYJ2 | Protein | SAL_10353 | Uncharacterized protein | NA | iTRAQ + ELISA | Unstimulated Saliva | Premalignant Disorder | Oral potentially malignant disorders | NA | 0.69 | Downregulated | NA | Homo sapiens | 30169911 | 2018 | Q6PJG0 | Protein | SAL_10355 | WW domain-binding protein 2 | NA | iTRAQ + ELISA | Unstimulated Saliva | Premalignant Disorder | Oral potentially malignant disorders | NA | 0.83 | Downregulated | NA | Homo sapiens | 30169911 | 2018 | Q969T9 | Protein | SAL_11741 | Alpha-1-antitrypsin | NA | LC-MS/MS + ELISA | Saliva | Premalignant Disorder | Dysplastic leukoplakia (LP) | NA | >1.5 | Upregulated | NA | Homo sapiens | 31706945 | 2019 | P01009 | Protein | SAL_11742 | Antileukoproteinase | NA | LC-MS/MS + ELISA | Saliva | Premalignant Disorder | Dysplastic leukoplakia (LP) | NA | >1.5 | Upregulated | NA | Homo sapiens | 31706945 | 2019 | P03973 | Protein | SAL_11743 | Apoptosis-associated speck-like protein containing a CARD isoform b | NA | LC-MS/MS + ELISA | Saliva | Premalignant Disorder | Dysplastic leukoplakia (LP) | NA | >1.5 | Upregulated | NA | Homo sapiens | 31706945 | 2019 | Q9ULZ3 | Protein | SAL_11744 | CD44 antigen | NA | LC-MS/MS + ELISA | Saliva | Premalignant Disorder | Dysplastic leukoplakia (LP) | NA | >1.5 | Upregulated | NA | Homo sapiens | 31706945 | 2019 | P16070 | Protein | SAL_11745 | Collagen alpha-1(I) chain protein | NA | LC-MS/MS + ELISA | Saliva | Premalignant Disorder | Dysplastic leukoplakia (LP) | NA | >1.5 | Upregulated | NA | Homo sapiens | 31706945 | 2019 | P02452 | Protein | SAL_11746 | Collagen alpha-1(III) chain protein | NA | LC-MS/MS + ELISA | Saliva | Premalignant Disorder | Dysplastic leukoplakia (LP) | NA | >1.5 | Upregulated | NA | Homo sapiens | 31706945 | 2019 | P02461 | Protein | SAL_11747 | Collagen alpha-1(V) chain protein | NA | LC-MS/MS + ELISA | Saliva | Premalignant Disorder | Dysplastic leukoplakia (LP) | NA | >1.5 | Upregulated | NA | Homo sapiens | 31706945 | 2019 | P20908 | Protein | SAL_11748 | Complement factor H | NA | LC-MS/MS + ELISA | Saliva | Premalignant Disorder | Dysplastic leukoplakia (LP) | NA | >1.5 | Upregulated | NA | Homo sapiens | 31706945 | 2019 | P08603 | Protein | SAL_11749 | Eosinophil cationic protein | NA | LC-MS/MS + ELISA | Saliva | Premalignant Disorder | Dysplastic leukoplakia (LP) | NA | >1.5 | Upregulated | NA | Homo sapiens | 31706945 | 2019 | P12724 | Protein | SAL_11750 | Hepatocyte growth factor-like protein precursor | NA | LC-MS/MS + ELISA | Saliva | Premalignant Disorder | Dysplastic leukoplakia (LP) | NA | >1.5 | Upregulated | NA | Homo sapiens | 31706945 | 2019 | P26927 | Protein | SAL_11751 | Heterogeneous nuclear ribonucleoproteins C1/C2 isoform b | NA | LC-MS/MS + ELISA | Saliva | Premalignant Disorder | Dysplastic leukoplakia (LP) | NA | >1.5 | Upregulated | NA | Homo sapiens | 31706945 | 2019 | P07910 | Protein | SAL_11752 | Integrin beta-2 precursor | NA | LC-MS/MS + ELISA | Saliva | Premalignant Disorder | Dysplastic leukoplakia (LP) | NA | >1.5 | Upregulated | NA | Homo sapiens | 31706945 | 2019 | P05107 | Protein | SAL_11753 | Kallikrein-1 preproprotein | NA | LC-MS/MS + ELISA | Saliva | Premalignant Disorder | Dysplastic leukoplakia (LP) | NA | >1.5 | Upregulated | NA | Homo sapiens | 31706945 | 2019 | P06870 | Protein | SAL_11754 | Keratin, type II cytoskeletal 6B | NA | LC-MS/MS + ELISA | Saliva | Premalignant Disorder | Dysplastic leukoplakia (LP) | NA | >1.5 | Upregulated | NA | Homo sapiens | 31706945 | 2019 | P04259 | Protein | SAL_11755 | Kininogen-1 isoform 2 precursor | NA | LC-MS/MS + ELISA | Saliva | Premalignant Disorder | Dysplastic leukoplakia (LP) | NA | >1.5 | Upregulated | NA | Homo sapiens | 31706945 | 2019 | P01042 | Protein | SAL_11756 | Leucine-rich alpha-2-glycoprotein | NA | LC-MS/MS + ELISA | Saliva | Premalignant Disorder | Dysplastic leukoplakia (LP) | NA | >1.5 | Upregulated | NA | Homo sapiens | 31706945 | 2019 | P02750 | Protein | SAL_11757 | Protein AMBP preproprotein | NA | LC-MS/MS + ELISA | Saliva | Premalignant Disorder | Dysplastic leukoplakia (LP) | NA | >1.5 | Upregulated | NA | Homo sapiens | 31706945 | 2019 | P02760 | Protein | SAL_11758 | Protein S100-A11 | NA | LC-MS/MS + ELISA | Saliva | Premalignant Disorder | Dysplastic leukoplakia (LP) | NA | >1.5 | Upregulated | NA | Homo sapiens | 31706945 | 2019 | P31949 | Protein | SAL_11759 | Protein S100-A12 | NA | LC-MS/MS + ELISA | Saliva | Premalignant Disorder | Dysplastic leukoplakia (LP) | NA | >1.5 | Upregulated | NA | Homo sapiens | 31706945 | 2019 | P80511 | Protein | SAL_11760 | Protein S100-A7 | NA | LC-MS/MS + ELISA | Saliva | Premalignant Disorder | Dysplastic leukoplakia (LP) | NA | >1.5 | Upregulated | NA | Homo sapiens | 31706945 | 2019 | P31151 | Protein | SAL_11761 | Protein S100-A7A | NA | LC-MS/MS + ELISA | Saliva | Premalignant Disorder | Dysplastic leukoplakia (LP) | NA | >1.5 | Upregulated | NA | Homo sapiens | 31706945 | 2019 | Q86SG5 | Protein | SAL_11762 | Protein S100-P | NA | LC-MS/MS + ELISA | Saliva | Premalignant Disorder | Dysplastic leukoplakia (LP) | NA | >1.5 | Upregulated | NA | Homo sapiens | 31706945 | 2019 | P25815 | Protein | SAL_11763 | Serpin B4 | NA | LC-MS/MS + ELISA | Saliva | Premalignant Disorder | Dysplastic leukoplakia (LP) | NA | >1.5 | Upregulated | NA | Homo sapiens | 31706945 | 2019 | P48594 | Protein | SAL_11764 | Serum amyloid P-component precursor | NA | LC-MS/MS + ELISA | Saliva | Premalignant Disorder | Dysplastic leukoplakia (LP) | NA | >1.5 | Upregulated | NA | Homo sapiens | 31706945 | 2019 | P02743 | Protein | SAL_11765 | Thrombospondin-1 precursor | NA | LC-MS/MS + ELISA | Saliva | Premalignant Disorder | Dysplastic leukoplakia (LP) | NA | >1.5 | Upregulated | NA | Homo sapiens | 31706945 | 2019 | P07996 | Protein | SAL_11766 | Thymidine phosphorylase isoform 1 proprotein | NA | LC-MS/MS + ELISA | Saliva | Premalignant Disorder | Dysplastic leukoplakia (LP) | NA | >1.5 | Upregulated | NA | Homo sapiens | 31706945 | 2019 | P19971 | Protein | SAL_11767 | Thyroxine-binding globulin precursor | NA | LC-MS/MS + ELISA | Saliva | Premalignant Disorder | Dysplastic leukoplakia (LP) | NA | >1.5 | Upregulated | NA | Homo sapiens | 31706945 | 2019 | P05543 | Protein | SAL_11768 | UV excision repair protein RAD23 homolog B isoform 1 | NA | LC-MS/MS + ELISA | Saliva | Premalignant Disorder | Dysplastic leukoplakia (LP) | NA | >1.5 | Upregulated | NA | Homo sapiens | 31706945 | 2019 | P54727 | Protein | SAL_11769 | Vasodilator-stimulated phosphoprotein | NA | LC-MS/MS + ELISA | Saliva | Premalignant Disorder | Dysplastic leukoplakia (LP) | NA | >1.5 | Upregulated | NA | Homo sapiens | 31706945 | 2019 | P50552 | Protein | SAL_11770 | Vitronectin precursor | NA | LC-MS/MS + ELISA | Saliva | Premalignant Disorder | Dysplastic leukoplakia (LP) | NA | >1.5 | Upregulated | NA | Homo sapiens | 31706945 | 2019 | P04004 | Protein | SAL_11907 | S100A7 | Diagnostic | ELISA | Whole Saliva | Premalignant Disorder | Oral submucous fibrosis | NA | NA | Upregulated | NA | Homo sapiens | 32334479 | 2020 | P31151 | Protein | SAL_16502 | Arginine | NA | CE-TOFMS | Saliva | Premalignant Disorder | Oral epithelial dysplasia | NA | NA | NA | NA | Homo sapiens | 30539290 | 2019 | 6322 | Metabolite | SAL_16505 | Carnitine | NA | CE-TOFMS | Saliva | Premalignant Disorder | Oral epithelial dysplasia | NA | NA | NA | NA | Homo sapiens | 30539290 | 2019 | 288 | Metabolite | SAL_16508 | N-Acetylglucosamine-1-phosphate | NA | CE-TOFMS | Saliva | Premalignant Disorder | Oral epithelial dysplasia | NA | NA | NA | NA | Homo sapiens | 30539290 | 2019 | 440272 | Metabolite | SAL_16511 | o-Hydroxybenzoate | NA | CE-TOFMS | Saliva | Premalignant Disorder | Oral epithelial dysplasia | NA | NA | NA | NA | Homo sapiens | 30539290 | 2019 | 54675850 | Metabolite | SAL_16514 | Ornithine | NA | CE-TOFMS | Saliva | Premalignant Disorder | Oral epithelial dysplasia | NA | NA | NA | NA | Homo sapiens | 30539290 | 2019 | 6262 | Metabolite | SAL_16517 | ribose 5-phosphate | NA | CE-TOFMS | Saliva | Premalignant Disorder | Oral epithelial dysplasia | NA | NA | NA | NA | Homo sapiens | 30539290 | 2019 | 77982 | Metabolite | SAL_16520 | (S)-Ureidoglycolic acid | Diagnostic | Q-TOF-liquid chromatography-mass spectrometry | Saliva | Premalignant Disorder | Oral leukoplakia | NA | 9.974 | Upregulated | NA | Homo sapiens | 30714209 | 2019 | 439269 | Metabolite | SAL_16522 | 1-methylhistidine | NA | CE-TOFMS | Saliva | Premalignant Disorder | Oral leukoplakia | NA | 15.170439 | Upregulated | NA | Homo sapiens | 30714209 | 2019 | 92105 | Metabolite | SAL_16524 | 12-amino-octadecanoic acid | Diagnostic | Q-TOF-liquid chromatography-mass spectrometry | Saliva | Premalignant Disorder | Oral leukoplakia | NA | -10.148185 | Downregulated | NA | Homo sapiens | 30714209 | 2019 | 5312961 | Metabolite | SAL_16526 | 13-cis-retinol | NA | CE-TOFMS | Saliva | Premalignant Disorder | Oral leukoplakia | NA | 11.23105 | Upregulated | NA | Homo sapiens | 30714209 | 2019 | 9904001 | Metabolite | SAL_16528 | 16-iodo-hexadecanoic acid | NA | CE-TOFMS | Saliva | Premalignant Disorder | Oral leukoplakia | NA | 16.46654 | Upregulated | NA | Homo sapiens | 30714209 | 2019 | 41111 | Metabolite | SAL_16530 | 17beta-Estradiol | NA | CE-TOFMS | Saliva | Premalignant Disorder | Oral leukoplakia | NA | 12.7399435 | Upregulated | NA | Homo sapiens | 30714209 | 2019 | 5757 | Metabolite | SAL_16532 | 2-Hydroxymestranol | NA | CE-TOFMS | Saliva | Premalignant Disorder | Oral leukoplakia | NA | 10.119617 | Upregulated | NA | Homo sapiens | 30714209 | 2019 | 198049 | Metabolite | SAL_16534 | 2-Oxoarginine | Diagnostic | Q-TOF-liquid chromatography-mass spectrometry | Saliva | Premalignant Disorder | Oral leukoplakia | NA | 17.555275 | Upregulated | NA | Homo sapiens | 30714209 | 2019 | 558 | Metabolite | SAL_16536 | 3-Hydroxylidocaine glucuronide | Diagnostic | Q-TOF-liquid chromatography-mass spectrometry | Saliva | Premalignant Disorder | Oral leukoplakia | NA | -11.584233 | Downregulated | NA | Homo sapiens | 30714209 | 2019 | 101705702 | Metabolite | SAL_16538 | 4-Hydroxyaminoquinoline N-oxide | Diagnostic | Q-TOF-liquid chromatography-mass spectrometry | Saliva | Premalignant Disorder | Oral leukoplakia | NA | 13.103778 | Upregulated | NA | Homo sapiens | 30714209 | 2019 | 5360001 | Metabolite | SAL_16540 | 4-Nitroquinoline-1-oxide | Diagnostic | Q-TOF-liquid chromatography-mass spectrometry | Saliva | Premalignant Disorder | Oral leukoplakia | NA | 6.774 | Upregulated | NA | Homo sapiens | 30714209 | 2019 | 5955 | Metabolite | SAL_16542 | 6 beta-Hydroxytriamcinolone acetonide | NA | CE-TOFMS | Saliva | Premalignant Disorder | Oral leukoplakia | NA | 18.346615 | Upregulated | NA | Homo sapiens | 30714209 | 2019 | NA | Metabolite | SAL_16544 | 9-chloro-10-hydroxy-hexadecanoic acid | Diagnostic | Q-TOF-liquid chromatography-mass spectrometry | Saliva | Premalignant Disorder | Oral leukoplakia | NA | 8.606354 | Upregulated | NA | Homo sapiens | 30714209 | 2019 | 656826 | Metabolite | SAL_16546 | D-Glycerate-2-phosphate | NA | CE-TOFMS | Saliva | Premalignant Disorder | Oral leukoplakia | NA | 0.2286948 | Upregulated | NA | Homo sapiens | 30714209 | 2019 | 439278 | Metabolite | SAL_16548 | D-Urobilinogen | Diagnostic | Q-TOF-liquid chromatography-mass spectrometry | Saliva | Premalignant Disorder | Oral leukoplakia | NA | 12.702057 | Upregulated | NA | Homo sapiens | 30714209 | 2019 | 440784 | Metabolite | SAL_16550 | Deoxycholic acid disulfate | NA | CE-TOFMS | Saliva | Premalignant Disorder | Oral leukoplakia | NA | 17.007912 | Upregulated | NA | Homo sapiens | 30714209 | 2019 | 457190 | Metabolite | SAL_16552 | Deoxypodophyllotoxin | Diagnostic | Q-TOF-liquid chromatography-mass spectrometry | Saliva | Premalignant Disorder | Oral leukoplakia | NA | -9.543235 | Downregulated | NA | Homo sapiens | 30714209 | 2019 | 345501 | Metabolite | SAL_16554 | Dextrorphan sulfate | Diagnostic | Q-TOF-liquid chromatography-mass spectrometry | Saliva | Premalignant Disorder | Oral leukoplakia | NA | 14.292724 | Upregulated | NA | Homo sapiens | 30714209 | 2019 | 92135625 | Metabolite | SAL_16556 | Dihydroisolysergic acid II | Diagnostic | Q-TOF-liquid chromatography-mass spectrometry | Saliva | Premalignant Disorder | Oral leukoplakia | NA | 15.05382 | Upregulated | NA | Homo sapiens | 30714209 | 2019 | 129723742 | Metabolite | SAL_16558 | Estradiol valerate | Diagnostic | Q-TOF-liquid chromatography-mass spectrometry | Saliva | Premalignant Disorder | Oral leukoplakia | NA | -11.359117 | Downregulated | NA | Homo sapiens | 30714209 | 2019 | 13791 | Metabolite | SAL_16560 | Estrone 3-glucuronide | Diagnostic | Q-TOF-liquid chromatography-mass spectrometry | Saliva | Premalignant Disorder | Oral leukoplakia | NA | 1.109 | Upregulated | NA | Homo sapiens | 30714209 | 2019 | 115255 | Metabolite | SAL_16562 | Estrone 3-sulfate | Diagnostic | Q-TOF-liquid chromatography-mass spectrometry | Saliva | Premalignant Disorder | Oral leukoplakia | NA | 16.48 | Upregulated | NA | Homo sapiens | 30714209 | 2019 | 3001028 | Metabolite | SAL_16564 | Etidronic acid | Diagnostic | Q-TOF-liquid chromatography-mass spectrometry | Saliva | Premalignant Disorder | Oral leukoplakia | NA | 2.515133 | Upregulated | NA | Homo sapiens | 30714209 | 2019 | 3305 | Metabolite | SAL_16566 | Etoposide glucuronide | NA | CE-TOFMS | Saliva | Premalignant Disorder | Oral leukoplakia | NA | 0.8115954 | Upregulated | NA | Homo sapiens | 30714209 | 2019 | 46173784 | Metabolite | |